The Cigna Group vs CLOVER HEALTH INVESTMENTS, CORP. /DE, two Managed Care stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CI and CLOV diverge most: on net margin, CI reads 2.2% and CLOV reads -0.7%; on return on equity, CI reads 14.5% and CLOV reads -4.9%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | CI | CLOV |
|---|---|---|
| Price | $280.76 | $4.83 |
| Market cap | $74.1B | $2.6B |
| Sector | Managed Care | Managed Care |
| Stage | Mature | Growth |
| P/E | 11.6 | — |
| P/B | 1.73 | 7.00 |
| P/S | 0.26 | 1.06 |
| EV/EBITDA | 5.6 | 60.9 |
| Revenue growth | +7.8% | +53.1% |
| Operating margin | 3.7% | 3.8% |
| Net margin | 2.2% | -0.7% |
| Return on equity | 14.5% | -4.9% |
| Return on assets | 4.0% | -2.5% |
| Return on invested capital | 18.1% | 8.7% |
| FCF yield | 13.9% | 2.8% |
| Dividend yield | 2.1% | — |
| Debt / equity | 0.07 | 0.00 |
| Current ratio | 0.85 | 1.50 |
| Altman Z (solvency) | 2.63 | 4.09 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.